showed similar results, namely, that Pro198Leu-associated GPx1 activities were decreased in breast cancer but were associated with increased breast cancer risk among Danish females [89]
Key facts for patients: Approved December 22, 2025
Ascletis has announced the selection of ASC35, a best-in-class once-monthly subcutaneous GLP-1R/GIPR dual peptide agonist, advancing toward clinical development for obesity and metabolic diseases
Anyone experiencing memory problems or cognitive changes should consult their GP for appropriate investigation, which may include cognitive screening, blood tests, and neuroimaging as per NICE guidance (NG97)
Does Fraxel laser tighten skin
Contact us today Personalized plans by clinical experts In-depth diagnostic testing before treatment begins Ongoing support for lasting results We start with advanced testing, turn your data into a personalized plan, and track progress to keep you improving